Santhera Pharmaceuticals announced preliminary revenue results for the full year 2016. For the period, the company reported revenue of CHF 19.0 million ($19.3 million) for the year, compared to CHF 4.3 million ($4.5 million) in 2015.

The company expects a net loss in between CHF 33 million ($33.5 million) and CHF 38 million ($38.6 million) for 2016, compared with net CHF 5.9 million ($6.1 million) gain in 2015.

The company has given guidance of CHF 21 million to CHF 23 million ($21.2 million to $23.2 million) in Raxone sales for 2017.